Kombinirovannaya terapiya patsientov s poyasnichnoy bol'yu


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Important problems of treatment of patient with low-back pain (LBP) include the elimination of pain and reversion of patient to normal life. Drugs are widely used for pain relief, primarily analgesics and nonsteroidal anti-inflammatory drugs (NSAIDs). Nimesulide is one of the drugs, which have long been used for the treatment of patients with pain syndromes caused by diseases of the musculoskeletal system, including LBP. Drugs that can provide structurally modifying effect, which not only eliminate the most important symptoms, but also affect the course of the disease, in particular slow the disease progression, are of justified interest. One of these drugs is chondroitin sulfate sodium (Chondrogard), and significant clinical experience of its use is gained.

Full Text

Restricted Access

References

  1. Kim T., Montejano L., Cao Z., Zhao Y. Health care costs in US patients with and without a diagnosis of osteoarthritis. J. Pain Res. 2012:5;23-30.
  2. Hall H., McIntosh G. Low back pain (acute) Clin Evid. 2008;2008:1102-108
  3. Schneider S., Schmitt H., Zoller S., Schiltenwolf M. Workplace stress, lifestyle and social factors as correlates of back pain: a representative study of the German working population. Int. Arch. Occup. Environ Health. 2005;78(4):253-69.
  4. Calvo-Munoz I., Gomez-Conesa A., Meca J. Prevalence of low back pain in children and adolescents: a meta-analysis. BMC Musculoskeletal Disorders. 2013; 13:55-9.
  5. Shehab D., Al-Jarallah K. Nonspecific low-back pain in Kuwaiti children and adolescents: associated factors. J. Adolesc. Health. 2005;36(1):32-5.
  6. Никифоров А.С., Авакян Г.Н. Неврологические осложнения остеохондроза позвоночника. 2011. 256 c.
  7. Sharma H., Gupta R., Olivero W., et al. fMRI in patients with lumbar disc disease: a paradigm to study patients over time. J. Pain Res. 2011;4:401-5.
  8. Hagen K., Jamtvedt G., Hilde G., Winnem M. Bed rest bad for back pain, ineffective for sciatica. The updated Cochrane Review of bed rest for low back pain and sciatica. Spine. 2005;30:542-46.
  9. van Tulder M., Becker A., Bekkering T., et al. European guidelines for the management of acute nonspecific low back pain in primary care. Eur. Spine J. 2006;15(Suppl. 2): 169-91.
  10. Helin-Salmivaara A., Saarelainen S., Gro Nroos J., et al. Risk of upper gastrointestinal events with the use of various NSAIDs: A case-control study in a general population. Scandinavian J. Gastroenterol. 2007;42:923-32.
  11. Ding C. Do NSAID affect the progression of osteoarthritis? Inflammation. 2002; 26:139-42.
  12. Huskinsson E., Berry P., Gishen P. Effects of anti-inflammatory drugs on the progression of osteoarthritis of the knee. J. Rheumatol. 1995;22:1941-46.
  13. Suleyman H., Cadirci E., Albayrak A., Halici Z. Nimesulide is a selective COX-2 inhibitory, atypical non-steroidal anti-inflammatory drug. Curr. Med. Chem. 2008;15(3):278-83.
  14. Koseoglu B., Ozturk S. Kocak H. The effects of etodolac, nimesulid and naproxen sodium on the frequency of sister chromatid exchange after enclused third molars surgery. Yonsei. Med. J. 2008;49(5):742-47. Eur. Ann. Allergy Clin. Immunol. 2006;38(6): 182-517.
  15. Alotti N., Bodo E., Gombocz K., et al. Management of postoperative inflammatory response and pain with nimesulide after cardiac surger. Orv. Hetil. 2003;144(48): 2353-57.
  16. Omololu B., Alonge T., Ogunlade S., Aduroja O. Double blind clinical trial comparing the safety and efficacy of nimesulide (100mg) and diclofenac in osteoarthrosis of the hip and knee joints. West Afr. J. Med. 2005;24(2):128-33.
  17. Herrera J., Gonzalez M. Comparative evaluation of the effectiveness and tolerability of nimesulide versus rofecoxib taken once a day in the treatment of patients with knee osteoarthritis. Am. J. Ther. 2003; 10(6):468-72.
  18. Ilic K., Sefik-Bukilica M., Jankovic S., Vujasinovic-Stupar N. Efficacy and safety of two generic copies of nimesulide in patients with low back pain or knee osteoarthritis. Reumatismo. 2009;61(1):27-33.
  19. Pohjolainen T., Jekunen A., Autio L., Vuorela H. Treatment of acute low back pain with the COX-2-selective anti-inflammatory drug nimesulide: results of a randomized, doubleblind comparative trial versus ibuprofen. Spine. 2000;25(12):1579-85.
  20. Полякова Ю.В., Сивородова Л.Е., Симакова Е.С. и др. Применение препарата Немулекс в лечении суставного синдрома. РМЖ, Ревматология. 2013;5:310-15.
  21. Pilotto A., Seripa D., Franceschi M., et al. Genetic susceptibility to nonsteroidal antiinflammatory drug-related gastroduodenal bleeding: Role of cytochrome P450 2C9 polymorphisms. Gastroenterology. 2007;133:465-71.
  22. Rainsford K. Current status of the therapeutic uses and actions of the preferential cyclo-oxygenase-2 NSAID, nimesulide. Inflammopharmacology. 2006;14(3-4): 120-37.
  23. Lippielo L., Grande D. In vitro chondroprotection of glucosamine and chondroitin sulfate in a rabbit model of a OA and demonstration of metabolic synergy on chondrocyte in vitro. Ann. Rheum. Dis. 2000; 59(Suppl. 1 ):266-07.
  24. Wandel S., Juni Р., Tendal В., Nuesch Е. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ. 2010; 341:4675-80.
  25. Reichenbach S., Sterchi R., Scherer M., et al. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med. 2007;146:580-90.
  26. Алексеев В.В. Хондропротекторы в неврологии: основания к применению. Consilium Medicum. 2012;14;9:94-9.
  27. Pelletier J.-P. Comprehensive Strategies for the Treatment of Osteoarthritis Targeting Both Symptoms and Structural Changes. Eur. Musculosceletal. Rev. Osteoarthritis. EULAR. 2009:20-4.
  28. Conforti A., Leone R., Moretti U., et al. Adverse drug reactions related to the use of NSAIDs with a focus on nimesulide: results of spontaneous reporting from a Northern Italian area. Drug Saf. 2001;24:1081-90.
  29. Volpi N. Quality of different chondroi-tin sulfate preparations in relation to their therapeutic activity. J. Pharm. Pharmacol. 2009;61(10):1271-80.
  30. Volpi N. Oral absorption and bioavailability of ichthyic origin chondroitin sulfate in healthy male volunteers. Osteoarthritis Cartilage. 2003;11 (6):433-41.
  31. Volpi N. Oral bioavailability of chondroitin sulfate (Condrosulf) and its constituents in healthy male volunteers. Osteoarthritis Cartilage. 2002;10(10):768-77.
  32. Ronca F., Palmieri L., Panicucci P., Ronca G. Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis Cartilage. 1998;6(Suppl A):14-21.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies